key: cord-0804532-7e7qpenm
authors: Yi, Yang; Li, Junhua; Lai, Xinyuan; Zhang, Meng; Kuang, Yi; Bao, Yang-Oujie; Yu, Rong; Hong, Wei; Muturi, Elishiba; Xue, Heng; Wei, Hongping; Li, Tong; Zhuang, Hui; Qiao, Xue; Xiang, Kuanhui; Yang, Hang; Ye, Min
title: Natural triterpenoids from licorice potently inhibit SARS-CoV-2 infection
date: 2021-11-26
journal: J Adv Res
DOI: 10.1016/j.jare.2021.11.012
sha: 22e190406294c03bf13b8bb58bc221bba1ead64e
doc_id: 804532
cord_uid: 7e7qpenm

INTRODUCTION: The COVID-19 global epidemic caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) is a great public health emergency. Discovering antiviral drug candidates is urgent for the prevention and treatment of COVID-19. OBJECTIVES: This work aims to discover natural SARS-CoV-2 inhibitors from the traditional Chinese herbal medicine licorice. METHODS: We screened 125 small molecules from Glycyrrhiza uralensis Fisch. (licorice, Gan-Cao) by virtual ligand screening targeting the receptor-binding domain (RBD) of SARS-CoV-2 spike protein. Potential hit compounds were further evaluated by ELISA, SPR, luciferase assay, antiviral assay and pharmacokinetic study. RESULTS: The triterpenoids licorice-saponin A3 (A3) and glycyrrhetinic acid (GA) could potently inhibit SARS-CoV-2 infection, with EC(50) of 75 nM and 3.17 µM, respectively. Moreover, we revealed that A3 mainly targets the nsp7 protein, and GA binds to the spike protein RBD of SARS-CoV-2. CONCLUSION: In this work, we found GA and A3 from licorice potently inhibit SARS-CoV-2 infection by affecting the entry and replication of the virus. Our findings indicate that these triterpenoids may contribute to the clinical efficacy of licorice for COVID-19 and could be promising candidates for antiviral drug development.

Coronaviruses (CoVs), represent the largest RNA viruses identified thus far, and are a group of enveloped viruses with a positive single-stranded RNA genome [1] [2] [3] . The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2) has been a great threat to global public health. Specifically, SARS-CoV-2 Lambda variant exhibit higher infectivity and immune resistance [4] and Delta variant possessing highly transmissible contains mutations that confer partial immune 4 escape [5] . To develop clinically available SARS-CoV-2 inhibitors, a number of repurposed chemical or biological drugs have been evaluated [6, 7] . Unfortunately, recent clinical trials organized by the World Health Organization indicated that several promising drugs including remdesivir, hydroxychloroquine, and lopinavir had little effect on hospitalized patients with COVID-19 [8] . Therefore, the development of antiviral drugs is still a great demand.

In China, traditional Chinese medicine (TCM) treatment has been playing an important role in the effective control of COVID-19 [9] [10] [11] [12] . Glycyrrhiza uralensis Fisch. (licorice, Gan-Cao) is the most frequently used Chinese herbal medicines (top 1 among 179 herbs) for the treatment of COVID-19, and appears in 84% of 166 clinical herbal formulas [13] .

Its major compound glycyrrhizic acid have been reported to possess antiviral activities against H1N1 influenza and SARS-CoV viruses [14] [15] [16] . However, little is known on the inhibitory activities of licorice compounds on SARS-CoV-2.

The entry step of the SARS-CoV-2 viral particles -encompassing attachment to the host cell membrane and fusion -are mediated by the spike protein [17] [18] [19] . The RBD is a key functional component within the S protein that is responsible for binding of SARS-CoV-2 by ACE2 [20] . The complex crystal structure of the SARS-CoV-2 spike protein receptor-binding domain (RBD) bound to its receptor ACE2 (angiotensinconverting enzyme 2) has been resolved [20] [21] [22] . Meanwhile, it has been reported that certain peptides such as dalbavacin [23] and human intestinal defensin 5 [24] could directly bind to ACE2 with high affinity (K D 147 nM and 76.2 nM, respectively) to block its interaction with the SARS-CoV-2 spike protein. However, very few small molecules have been reported to target the RBD, thus far.

Natural and biosynthetic SARS-CoV-2 inhibitors against 3CL pro and PL pro have been reported in recent years [25] . This work aims to discover small-molecule inhibitors targeting SARS-CoV-2 spike protein RBD from licorice (Fig. 1A) . Here we report two licorice triterpenoids, namely licorice-saponin A3 (A3) and glycyrrhetinic acid (GA), which could potently inhibit SARS-CoV-2 with EC 50 values of 75 nM and 3.17 M, respectively. This finding reveals that triterpenoids from licorice could be promising drug candidates for COVID-19. 5 

Density functional theory (DFT) approach was used to optimize small molecules [26] [27] [28] [29] . All the structures were simulated by B3LYP/6-311G(d) method in the gas phase. All calculations for these small molecules were performed by utilizing the Gaussian09 suite of codes [30] and GaussView. Structures of the RBD (PDB ID: 6M0J) and nsp7 (PDB ID: 7JIT) were applied for protein-ligand calculations. Molecular Docking was performed by AutoDock Vina and AutoDocktools v1.5.6 softwares [31] .

Vero E6 cells (ATCC) and Caco-2 cells were cultured in high glucose DMEM (GIBCO) supplemented with 10% FBS (GIBCO), penicillin (100 IU/mL), and streptomycin (100 μg/mL) in a 5% CO 2 incubated at 37 °C, and were passaged every 2-3 days. Luciferase Assay System (E1500) was purchased from Promega (USA), and CCK8 kit (CK04) was purchased from Dojindo (Japan) for cytotoxicity test. SARS-CoV-2 strain (nCoV-2019BetaCoV/Wuhan/WIV04/2019) was propagated in Vero E6 or Caco-2 cells and titrated by standard plaque assay following the standard procedure.

All experiments related to authentic SARS-CoV-2 were conducted at the Zhengdian Biosafety Level 3 (BSL3) facility of Wuhan Institute of Virology. S-trimer protein, ACE2 and 3-chymotrypsin-like protease (3CL pro ) were from Novoprotein Technology Co., Ltd. RBD, RBD mutant (Y453F), RBD (L452Q, F490S), RBD (L452R), RBD (T478K) and nsp12 proteins were from Sino Biological Inc. All the drugs used in this study were from the compound library of the authors' laboratory.

The cDNA encoding residues 11843-12091 (nsp7) and 12092-12685 (nsp8) of ORF1ab inserted into pET-28b vector was synthesized. Then it was expressed in E. coli strain BL21 (DE3) as soluble proteins at 37 °C for 10 h, until OD 600 reached 0.5-0.7.

Then, isopropyl-β-D-thiogalactopyranoside was added (final concentration was 0.1 mM). Express the protein at 18 °C for 18-20 h. Then harvest the cells at 7,000 rpm, 3 min, 4 °C. Lysis buffer (50 mM NaH 2 PO 4 pH 8.0, 300 mM NaCl, 10 mM imidazole) was used for resuspension, and sonication in an ice bath was applied to disrupt cells.

Finally, the cell debris was removed by centrifugation at 9,000 rpm for 30 min at 4 °C. 6 The supernatant was collected and Ni-NTA affinity chromatography (Transgen, China) was used for protein purification. His-tag of the protein was digested and cut by thrombin. Then Ni-NTA was used to purify the protein for the second time. After ultrafiltration centrifugation, solvent of the protein solution was changed to the molecular sieve buffer (20 mM Tris-HCl, 100 mM NaCl, pH 7.5). A Superdex column (Superdex TM 200 Increase 10/300 GL) was used for further purification, eluted with a buffer (20 mM Tris-HCl, 100 mM NaCl, pH 7.5) at a flow rate of 0.5 mL/min.

Briefly, the spike protein (0.5 μg/mL) was diluted with coating solution (Na 2 CO 3 , 1.59 mg/mL; NaHCO 3 , 2.93 mg/mL; pH 9.6) and seeded on 96-well microplates at 4 C overnight. After washing the microplates using the wash buffer (PBS buffer with 0.05% Tween-20 (v/v)) three times, 2% bovine serum albumin in the wash solution was used to block the plates for 40 min at 37 °C. The small molecules at a final concentration of 80, 40, 20, 10, 5, 2.5 μM were then added (one hour before ACE2) after washing the microplates three times. ACE2 (0.5 μg/mL) was added and incubated for another one hour. Then enzyme-linked antibody SA-HRP (1:15000) (Sangon Biotech Co., Ltd, Shanghai) was added after ACE2 was washed. Tetramethyl benzidine (TMB) was used as the chromogenic agent. Finally, 1 M HCl was used to stop the reaction and the enzyme activity was determined at OD450 nm.

Cell viability was measured by Cell Counting Kit-8 (CCK-8, Dojindo, Japan) assay. Firstly, Vero E6 cells were planted in 96-well plates. The density was 1×10 4 cells/well (in DMEM+10%FBS). Vero E6 cells were incubated under conditions of 5% CO 2 at 37°C for 24 h. Then, testing molecules (maximum concentration at 100 μM, <1% DMSO) were diluted in DMEM culture medium and added to each well for another 24 h. The organic solvent in DMEM was less than 0.1%. 24 h after drug addition, the contents of the wells were substituted with fresh medium containing 10% CCK-8 solution and incubated at 37°C for 3 h. And the final optical density at OD450 was determined using Synergy Microplate reader.

SARS-CoV-2 pseudovirus preparation and infection assay were conducted according to published literature [32] . Vero E6 cells were planted in 96-well plates with 20,000 cells/well and then cells were infected with viral inocula of 650 TCID 50 /well. After 24 h, the cells were lysed, then the mixture was prepared by 20 µL of samples and 100 µL of Luciferase Assay Reagent (Promega, USA). Luminescence was measured with a microplate luminometer (PerkinElmer, USA). 

ACE2, RBD, the spike protein, nsp7, nsp8, and nsp12 were respectively immobilized to the sensor chip CM5 according to primary amine coupling reaction.

Biacore T200 was used and running buffer was PBS containing 5% DMSO with 0.05% P20. The proteins were diluted with sodium acetate solution at 10 mM, pH 4.5 for ACE2

and nsp12, and pH 5. 

Firstly, we screened 125 licorice compounds by molecular docking using AutoDock VINA (Supplementary Table S1 ). Structures of the natural products were optimized by density functional theory (DFT), and the RBD structure extracted from the RBD/ACE2 complex (PDB ID: 6M0J) was used for initial screening [20] . The location of residues R403, Q498, and T500 was determined as the binding site.

Noticeably, majority of the compounds with high binding affinities were triterpenoid saponins (the glycosides of triterpenoids), together with the free triterpenoid glycyrrhetinic acid (GA). Then, we set the interactive area of RBD and ACE2 as the binding site to further screen 21 triterpenoids with high RBD affinities (< -7.0 kcal/mol or -29.2 kJ/mol) using the RBD/ACE2 complex structure (Fig. 1B, Supplementary Fig.   S1 ; Table S2 ). Interestingly, GA, 3-O-β-D-glucuronosyl-glycyrrhetinic acid (GA-g), and licorice-saponin A3 (A3) showed remarkably higher affinities than glycyrrhizic acid (GA-gg), which had been reported as a SARS-CoV-2 inhibitor [34] .

Next, we determined inhibitory activities of the licorice compounds against SARS-CoV-2 spike protein by ELISA. At 10 µM, GA, GA-g, and A3 exhibited inhibition rates of 51.9%, 50.2% and 45.1%, respectively, which were remarkably higher than the other licorice compounds including GA-gg ( Supplementary Fig. S2A ). We also tested six non-licorice triterpenoids with similar structures to GA (Supplementary Fig. S2B) . 

Then we tested the inhibitory activities of the above five hit compounds against the infection of SARS-CoV-2 pseudovirus on Vero E6 cells. Skimmed breastmilk A17 was used as the positive control [32] . Three assays, including "blocking", "attachment", 12 and "entry", were designed to investigate the inhibition mode. GA, GA-g, and A3

showed significant inhibitory activities in all the three procedures at 10 µM (Fig. 1D ).

In the "blocking" assay, GA, GA-g, and A3 exhibited remarkable anti-viral infection activities, with EC 50 values of 4.98, 5.37, and 9.30 µM, respectively (Fig. 1E) . Although ursolic acid and betulinic acid also showed noticeable effects, they exhibited remarkable cytotoxicity and were not further evaluated ( Supplementary Fig. S3A-B) . Consistent with the ELISA experiments, GA-gg showed weak activities in the pseudovirus system ( Supplementary Fig. S3C-D) . We also constructed a neutralization assay to visualize the anti-viral infections caused by GA, GA-g, and A3 in Vero E6 cells ( Supplementary   Fig. S4 ). GA and A3 inhibited SARS-CoV-2 pseudovirus with an inhibition rate of > 90% at 80 µM, which was similar to A17 at 4 mg/mL. Given the relatively weak activity of GA-g, we focused on GA and A3 for follow-up experiments.

SPR (surface plasmon resonance) analysis indicated that GA and A3 could tightly bind to the RBD of SARS-CoV-2 spike protein, but GA-g and GA-gg only showed very weak bindings (Supplementary Fig. S5 ). The K D values of GA and A3 with RBD were 2.33 and 33.6 μM, respectively ( Fig. 2A) . Molecular docking analysis indicated that GA, GA-g, GA-gg, and A3 formed three, two, one, and three hydrogen bonds with surrounding amino acids, respectively (Fig. 2B) . The 3-OH, 11-C=O, and 30-COOH of GA formed hydrogen bonds with Y453, N501, and G502, respectively. Due to the existence of 3-O-glucuronyl residue, two hydrogen bonds could be formed for GA-g, i.e., 4-OH/Y453, and 11-C=O/G502. For GA-gg, the 3-OH is substituted with two glucuronyl groups, and 11-C=O and 30-COOH are extruded from the binding pocket.

Thus, only one hydrogen bond was formed, i.e., 4-OH and Y453. Interestingly, when the 30-COOH is attached with a glucosyl group, the structure of A3 exactly matches the binding pocket. The 6-COOH of 2-O-glucuronyl, 6-COOH of 3-O-glucuronyl, and 6-OH of 30-glucosyl residue interact with Y453, N501, and G446, respectively.

These hydrogen bond interactions determined the binding affinities, and were consistent with the structure-activity relationships of SPR analysis. We noticed that Y453 could bind to all the four triterpenoids. Therefore, we determined the inhibitory activities of the drugs at 10 M by ELISA against the spike RBD and its Y453F mutant, respectively.

All four triterpenoids showed remarkably decreased inhibitions, indicating that Y453 is 13 a key residue for the binding of triterpenoids with spike RBD (Fig. 2C ). According to crucial role of L452, further study was focused on inhibitory activities of GA and A3 against RBD L452Q/F490S, L452R and T478K mutants related to Lambda (C.37) and

Delta (B.1.617.2) variants, respectively. Fortunately, both GA and A3 possessed inhibitory activities against these mutants although inhibition decreased around 10% comparing to RBD (Supplementary Fig. S6 ).

Subsequently, we tested inhibitory activities of the triterpenoids against SARS-CoV-2 virus in Vero E6 cells. Remdesivir was used as the positive control. Compared to GA-g and GA-gg, both GA and A3 showed significant inhibitory activities at 3 µM (Fig. 3A) . The viral RNA level in cells decreased in a dose-dependent manner upon the treatment of GA with EC 50 of 3.17 µM (Fig. 3B) . Unexpectedly, A3 showed very potent inhibitory activity with EC 50 of 75 nM (Fig. 3B) . The inhibition could still be observed at 48 h post-infection ( Supplementary Fig. S7 ). We further tested the antiviral activities of A3 in the human colon adenocarcinoma Caco-2 cells. A3 showed an inhibition rate of >75% at 0.3 M (Fig. 3C ). An indirect immunofluorescence assay (IFA) was conducted to verify the antiviral effects. Consistently, GA and A3 remarkably inhibited the SARS-CoV-2 virus in a dose-dependent manner (Fig. 3D) , when compared with the drug-free mock cells.

Given its nanomolar level inhibitory activity against SARS-CoV-2, A3 should have other targets than the spike protein [35] . Thus, we tested the activities of A3 against 3CL pro , the other important target for SARS-CoV-2 infection [36] . A3 only showed an inhibition of 14.37% at 10 µM, indicating 3CL pro was not a target for A3. RNAdependent RNA polymerase (RdRp) is also a critical target for SARS-CoV-2. The nonstructural proteins nsp12, nsp7, and nsp8 are essential components of RdRp. Nsp12 is the catalytic subunit, and nsp7 and nsp8 are cofactors [37] . While we failed to establish the RdRp assay, we determined the binding of A3 and GA with nsp12, nsp7, and nsp8, respectively. The SPR results showed that A3 could bind with nsp7 much more tightly than with the other two proteins, with K D values of 167 nM, 15.5 M, and 67.5 M for nsp7, nsp8, and nsp12, respectively ( Fig. 4A; Supplementary Fig. S8 ). In 14 contrast, GA only showed very weak binding affinities, with K D values of 384, 91.2, and 416 μM, respectively ( Fig. 4B; Supplementary Fig. S8 ). Molecular docking of A3 with nsp7 extracted from the nsp7-nsp8 complex crystal structure (PDB ID:7JIT) demonstrated seven hydrogen bonds, and the binding energy was -8.7 kcal/mol (Fig.   4C ). These data indicated that nsp7 may be the target for A3.

The rats maximum plasma concentration was 5. Supplementary Fig. S9 ). These results indicated both GA and GA-gg could be absorbed into circulation, and that they could be inter-converted.

Although the concentration of GA in licorice or Lianhuaqingwen is very low, the abundant GA-gg could be readily metabolized into GA, which is active for SARS-CoV-2. More importantly, the elimination of GA in rats was slow, and the concentration remained at high levels between 8-24 h. GA could also be detected in the lung tissue, which is a key target organ for COVID-19 (Fig. 5D ).

Given that A3 may be metabolized into GA-gg by gastrointestinal microbiota, it was given to rats by intravenous injection (i.v., 20 mg/kg). A3 showed a first-order elimination and the elimination rate was slow, with the plasma concentration decreased from 48.9 µM at 1 h to 27.3 µM at 24 h (Fig. 5E) . Only a small portion of A3 was metabolized into GA-gg, GA-g, and GA.

Although traditional Chinese medicines have been widely used in China for the prevention and treatment of COVID-19, very few antiviral compounds have been discovered and investigated in-depth. Meanwhile, licorice is the most frequently used herb in TCM formulas against COVID-19 [13] , and its bioactive compounds remain unknown.

Our study screened 125 compounds from licorice and showed that licorice-saponin A3 and glycyrrhetinic acid are potent inhibitory compounds against SARS-CoV-2 virus.

Moreover, this work provides important experimental evidences for presenting the clinical efficacy of licorice and related TCM products. 15 To our knowledge, A3 (EC 50 75 nM) possesses promising anti-SARS-CoV-2 activity, compared to 11a (0.53 µM), remdesivir (0.77 µM), calpeptin (72 nM), and MI-30 (0.54 µM in Vero E6 cells, and 1.1 nM in HPAEpiC cells) [36, [38] [39] [40] . Natural triterpenoids have been reported to be antiviral agents against a wide spectrum of viruses including HIV-1 and influenza A [35] . While the abundant licorice compound GA-gg shows weak antiviral activities [41] and may reduce ACE2 expression in the lung [16] , it could be readily metabolized into the active form GA. This may be one mechanism for the clinical therapeutic effects of licorice and its compound formulas 

In this work, we find that A3 and GA potently inhibit SARS-CoV-2 by targeting nsp7 and spike protein RBD, respectively. Although the potential of GA had been reported by molecular docking calculations and protein inhibition assay, the anti-SARS-CoV-2 activities of GA and A3 were reported in this work for the first time. It is 16 interesting that A3 and GA, which have the same triterpenoid skeleton, have different targets. This "multi-components, multi-targets" mode of action is a unique feature for herbal medicines and contributes to the overall clinical effects of licorice in the treatment of COVID-19.

The animal facilities and protocols were approved by the Animal Care and Use Committee of Peking University Health Science Center (SYXK 2016-0041). All animal care and experimental procedures in this work were in accordance with Guide for the Care and Use of Laboratory Animals (National Institutes of Health).

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

Coronaviridae: a review of coronaviruses and toroviruses

A decade after SARS: strategies for controlling emerging coronaviruses

A pneumonia outbreak associated with a new coronavirus of probable bat origin

SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance

Shedding of Infectious SARS-CoV

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

The place for remdesivir in COVID-19 treatment

Repurposed antiviral drugs for COVID-19-interim WHO SOLIDARITY trial results

Bioactive natural compounds against human coronaviruses: a review and perspective

Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein

Lianhuaqingwen exerts anti-viral and antiinflammatory activity against novel coronavirus (SARS-CoV-2)

Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening

Analysis on herbal medicines utilized for treatment of COVID-19

Bioactive constituents of Glycyrrhiza uralensis (Licorice): discovery of the effective components of a traditional herbal medicine

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Symptomatic protective action of glycyrrhizin (Licorice) in COVID-19 Infection? Front Immunol

Mechanisms of SARS-CoV-2 entry into cells

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Coronaviruses: an overview of their replication and pathogenesis

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

situ structural analysis of SARS

CoV-2 spike reveals flexibility mediated by three hinges

Computational alanine scanning and structural analysis of the SAR-S-CoV-2 spike protein/Angiotensin-Converting Enzyme 2 complex

Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and its effective in inhibiting SARS-CoV-2 infection in animal models

Human intestinal defensin 5 inhibits SARS-CoV-2 invasion by cloaking ACE2

An overview of potential inhibitors targeting non-structural proteins 3 (PL pro and Mac1) and 5 (3CL pro /M pro ) of SARS-CoV-2

Density-functional thermochemistry. III. The role of exact exchange

Development of the Colle-Salvetti correlationenergy formula into a functional of the electron density

Results obtained with the correlation-energy density functionals of Becke and Lee, Yang and Parr

Contracted Gaussian-basis sets for molecular calculations

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

The effect of whey protein on viral infection and replication of SARS-CoV-2 and pangolin coronavirus in vitro

Robust neutralization assay based on SARS

S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells

Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2

Triterpenoid-mediated inhibition of virus-host interaction: is now the time for discovering viral entry/release inhibitors from nature?

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease

SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model

an active component of liquorice roots, and replication of SARS-associated coronavirus

• Systemic approach to discover SARS-CoV-2 inhibitors from the herbal medicine licorice. • Licorice-saponin A3 and glycyrrhetinic acid inhibit SARS-CoV-2 by targeting nsp7 and the S-RBD, respectively. • Drug potential of these compounds were confirmed by cell models and by PK studies.• The "multi-component, multi-target" mode of action was demonstrated for herbal medicines.• Licorice triterpenoids could be promising candidates for anti-SARS-CoV-2 drug development. 27 

The authors have declared no conflict of interest